The Mystery and Magic of Glia: A Perspective on Their Roles in Health and Disease  by Barres, Ben A.
Neuron
Perspective
The Mystery and Magic of Glia:
A Perspective on Their Roles in Health and Disease
Ben A. Barres1,*
1Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305, USA
*Correspondence: barres@stanford.edu
DOI 10.1016/j.neuron.2008.10.013
In this perspective, I review recent evidence that glial cells are critical participants in every major aspect of
brain development, function, and disease. Far more active than once thought, glial cells powerfully control
synapse formation, function, and blood flow. They secretemany substanceswhose roles are not understood,
and they are central players in CNS injury and disease. I argue that until the roles of nonneuronal cells are
more fully understood and considered, neurobiology as a whole will progress only slowly.Introduction
Twenty years ago, George Somjen began his excellent review on
the history of glia by noting how much of today’s research is still
directed toward answering questions first asked a century ago
(Somjen, 1988). Indeed my students, so sure of the rapid pace
of science today, are surprised when I tell them that they are still
investigating exactly the same questions that my graduate stu-
dent contemporaries investigated 25 years ago. Though there
has been a great deal of progress, most fundamental questions
about brain development, function, and disease are still relatively
poorly understood. How do synapses form, stabilize, and
achieve their specificity? How do we learn and remember?
How are neurons and glia generated? How does myelination
happen? Why don’t severed CNS axons regenerate and why
do synapses degenerate in Alzheimer’s disease? Fortunately,
thanks to the power of modern tools, the rate of progress is
ramping up, so that the average student today can generally
make mechanistic, rather than solely descriptive, steps forward.
Here I will focus on the role of glial cells in the development and
function of neural circuitry, both in health and disease. As a young
neurologist in training, I became interested in the function of glial
cells during a neuropathology clerkship. As I looked at brain sec-
tions from various neurological diseases under the microscope, I
realized not only that at least half the volume of the human brain is
constituted by glial cells—astrocytes, oligodendrocytes, and mi-
croglial cells–but also how radically altered glial cell phenotype is
in every brain injury and disease. I became captivated by the
questions: what do glial cells normally do, and what is their role
in disease? Might glial cells be important drug targets? Through-
out this perspective, I will speculate often and without apology.
When it comes to understanding the mystery and magic of glia,
progress depends on guesswork. As Nobel Laureate Richard
Axel has put it: ‘‘Before you know, you must imagine.’’
What Do Astrocytes Do?
A Role for Astrocytes in Synapse Formation and
Plasticity
Astrocytes could be as heterogeneous as neurons. They fall into
at least two main classes distinguished by morphology, anti-
genic phenotype, and location. Accordingly, they most likely dif-
fer in some of their main functions. Protoplasmic astrocytes are430 Neuron 60, November 6, 2008 ª2008 Elsevier Inc.found in gray matter and their processes ensheath synapses as
well as blood vessels. Fibrillary (or fibrous) astrocytes in white
matter contact nodes of Ranvier and blood vessels. A single as-
trocyte extends thousands of fine membranous processes that
ensheath synapses and fine blood vessels and help fill the neuro-
pil (Araque et al., 1999; Ventura and Harris, 1999; Bushong et al.,
2002). There are specialized astrocytes, including Mu¨ller glia in
the retina and Bergmann glia in the cerebellum, that appear sim-
ilar to protoplasmic astrocytes in antigenic phenotype in that
they exist in gray matter and ensheath many synapses. Glia ex-
hibit remarkably similar morphologies in Drosophila, suggesting
that important glial functions are likely to be highly conserved.
What do astrocytes do at synapses? They help to control the
levels of some ions such as K+ ions and neurotransmitters in
the extracellular space. This is said in every textbook, yet our un-
derstanding of exactly how astrocytes control extracellular K+
and other ions is poorly understood and deserves fresh atten-
tion, particularly now that the full cassette of ion transporters,
pumps, and channels they express has been elucidated (Lovatt
et al., 2007; Cahoy et al., 2008). Astrocytes express receptors for
a wide variety of neurotransmitters, and can release many known
and unknown neuroactive substances, as well as trophic factors.
The functional significance of most of this signaling is mysteri-
ous, but it is likely to help control development and function of
synapses, blood vessel flow, and neuronal survival.
To try to better understand the role of astrocytes at synapses,
Pfrieger and Barres (1997) asked whether a highly purified CNS
neuron type, retinal ganglion cells, would form functional synap-
ses when cultured in the absence of all glial cells. They used ret-
inal ganglion cells because this is still one of the few CNS neuron
types that can be highly purified and cultured in defined, serum-
free medium at high survival in the total absence of glial cells. Al-
though purified retinal ganglion cells elaborated dendrites and
axons and are electrically excitable, they exhibit little synaptic
activity. In contrast, when cultured with astrocytes, or culture
medium that has been conditioned by astrocytes, their synaptic
activity increases by nearly 100-fold. In contrast, coculture with
other cell types such as fibroblasts and oligodendrocytes does
not enhance their synaptic activity, and the requirement for as-
trocyte signals persists even when the retinal ganglion cells are
cocultured with their normal target neurons from the superior
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due to enhancement of synapse number, synapse function, or
both? To find out, Ullian et al. (2001) used quantal analyses,
FM1-43 imaging, immunostaining, and electron microscopy to
determine that few synapses form between retinal ganglion cells
in culture in the absence of astrocytes, and that the few synapses
that do form are functionally immature. Astrocytes increase the
number of synapses that form by nearly 10-fold, but also strongly
enhance their presynaptic and postsynaptic function. Similarly,
Schwann cells promote the formation and maintenance of the
neuromuscular junction (Feng and Ko, 2008). These findings
demonstrated novel, active roles for astrocytes and Schwann
cells in promoting synapse formation and function in vitro. The
possibility that astrocytes might act similarly in vivo is strongly
suggested by the correlation between when and where synap-
ses form and the timing and localization of astrocyte generation
in vivo.
What are the signals that astrocytes release that promote CNS
synaptogenesis? Christopherson et al. (2005) found that astro-
cytes release a large matrix-associated protein called thrombo-
spondin (Figure 1). Thrombospondins consist of a family of five
homologous proteins, which all share the ability to induce synap-
togenesis. At least four of these family members are expressed
by astrocytes in the brain, particularly during development and
after injury. In addition TSP3 remains highly expressed in the nor-
mal adult hippocampus and thrombospondins are amongst the
few genes that are far more highly expressed in human brain
compared with primate brain (Caceres et al., 2006). Thrombo-
spondin is sufficient to induce synapses that have normal
presynaptic and postsynaptic ultrastructure as well as normal
clustering of presynaptic and postsynaptic proteins, such as
synapsin and PSD-95, respectively. These synapses, however,
are postsynaptically silent, lacking glutamate sensitivity. Astro-
cytes secrete a different protein, not yet identified, that induces
postsynaptic glutamate (AMPA) responsiveness (Christopher-
son et al., 2005). In addition, astrocyte-derived cholesterol pow-
erfully enhances presynaptic function by nearly 100-fold (Mauch
et al., 2001). Thrombospondin-1/2 null brains have significantly
decreased synapse number, providing evidence that astrocytes
Figure 1. The Formation of Functional Synapses Is Controlled by
Astrocytes in Multiple Steps
Astrocytes secrete proteins called thrombospondins (TSP) that induce
neurons to form synapses. The presynaptic function of these synapses
is strongly enhanced by astrocyte-secreted cholesterol. The postsynaptic
function of synapses, determined by the level of synaptic AMPA glutamate
receptors, is strongly enhanced by an as yet unidentified protein secreted
by astrocytes. Finally, astrocytes also help to control synapse elimination
by secreting an unidentified signal that induces neurons (and possibly also
microglia) to express and secrete C1q, which becomes synaptically local-
ized and leads to activation of the classical complement cascade (see
text).
normally help to promote synapse formation in vivo. More-
over the neuronal receptor that mediates thrombospondin-
induced synaptogenesis has recently been identified, and
antagonists of this receptor profoundly impair synaptogene-
sis in vitro and in vivo (C. Eroglu and B.B., unpublished data).
Thus, astrocytes secrete many signals that promote synapse
formation and function.
One of the great unsolved mysteries in understanding brain
development is how short-term changes in sensory activity in
neurons can permanently alter synaptic structure during a critical
window of brain development. Do astrocytes play a role in critical
period plasticity? The possibility that astrocytes may play an im-
portant role in this process has recently been reviewed (Eroglu
et al., 2008). One of the most provocative experiments was per-
formed by Christian Muller, who found that transplantation of
immature astrocytes into adult primary visual cortex of cats ro-
bustly restored ocular dominance plasticity (Mu¨ller and Best,
1989). The secretion of thrombospondins by immature astro-
cytes is under the control of ATP and other neurotransmitters
(Tran and Neary, 2006), suggesting the possibility that neuronal
activity may control the ability of astrocytes to promote synapto-
genesis. Moreover thrombospondin has been found to be one of
the few genes that are highly upregulated in human brain com-
pared with primate brain, suggesting that it may contribute to
the greatly enhanced brain plasticity of humans. Removal of in-
appropriate synaptic connections is also a critical component
of brain plasticity (Boulanger and Shatz, 2004), a process which
astrocytes also participate in (see below). Thus, understanding
the role of astrocytes in structural synaptic plasticity promises
to be a fruitful area for future investigation in understanding
how to build neural circuits as well as how to rebuild them after
injury. What is as yet unclear is why a neuron-glial interaction is
so critical for some, or all, of synaptogenesis. Presumably glial
cells play a critical role in controlling the timing, location, number,
function, and plasticity of synapses, and perhaps in the evolution
of greater synaptic plasticity in human brains.
Glial CalciumWaves, Gliotransmission, and the Function
of Neural Circuits
Do astrocytes actively control neural circuit function in the adult
CNS? Astrocytes are highly secretory cells and given their prox-
imity to synapses, it is not surprising that there is emerging evi-
dence that glia secrete many different signals that control synap-
tic function. But exactly what these signals are, how they are
released, and what their functional significance might be are stillNeuron 60, November 6, 2008 ª2008 Elsevier Inc. 431
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known to induce robust intracellular calcium waves that propa-
gate between astrocytes in culture. Neurons release a variety
of substances such as ATP and glutamate that activate G protein
coupled receptors (GPCRs) in astrocytes, which leads to eleva-
tion of IP3 and IP3 receptors and calcium release from the endo-
plasmic reticulum (Agulhon et al., 2008). Only recently has it been
conclusively shown that neuronal activity in awake, mobile mice
is correlated with intracellular calcium transients in astrocytes
(Wang et al., 2006; Dombeck et al., 2007; Petzold et al., 2008;
Schummers et al., 2008). By imaging these calcium transients,
it has been found that astrocytes, like neurons, respond to visual
stimuli with distinct spatial receptive fields and sharp tuning to vi-
sual stimulus features including orientation and spatial frequency
(Schummers et al., 2008). Surprisingly, Schummers et al. (2008)
found that these astrocyte calcium waves generally did not prop-
agate to other astrocytes in vivo, providing evidence that astro-
cytes can respond as individual cells, much like neurons, with
their own unique response patterns.
All of these groups found that calcium waves in astrocytes cor-
relate with increased microvascular blood flow. Although this
might just be a correlation, a variety of pharmacological manip-
ulations provide evidence that neuronal signals induce glial cells
to elevate their calcium levels and to release signals that regulate
vasodilation. Astrocytes can release either vasoconstrictors or
vasodilators depending on context (Zonta et al., 2003; Metea
and Newman, 2006; Gordon et al., 2007), but the nature of the
signals, relevant contexts, and functional significance is not yet
clear. Emerging data suggests that the extent of gap junction
coupling between astrocytes is very region and astrocyte depen-
dent, as well as strongly neuronal activity dependent, suggesting
the existence of glial circuits (Houades et al., 2006). This sug-
gests that glial gap junctions may help remove ions and toxin
metabolites from synapses, deliver nutrients, or both. This close
coupling between neurons, glia, and blood vessels has been
termed the neurovascular unit. Neurons, glia, and blood vessels
all work together in a close symbiosis to control our cognitive
functions, and impairments of this symbiosis correlate with,
and may well contribute to, diseases of cognitive dysfunction
such as Alzheimer’s disease (Takano et al., 2007). The signifi-
cance of the neurovascular unit for normal brain function and
brain dysfunction deserves much more attention.
A controversial question in glial biology has been whether
neuronal activity, by inducing calcium waves in astrocytes, in-
duces secretion of neuroactive substances from astrocytes
back onto synapses in a process known as gliotransmission.
Glutamate release at neuron-glial synapses onto NG2-positive
glial cells, oligodendrocyte precursor cells (OPCs), has been
conclusively demonstrated (Paukert and Bergles, 2006), al-
though its function is mysterious. It has been repeatedly
claimed, however, that astrocytes in vivo secrete quanta of glu-
tamate by regulated vesicular release. There are many reasons
to be skeptical. First, astrocytes, unlike neurons, are highly
enriched in the enzyme glutamine synthetase, which degrades
glutamate to glutamine. A variety of methods for measuring in-
tracellular glutamate concentrations suggest that whereas levels
of glutamate may approach 10 mM within neurons, glutamate
does not exceed housekeeping levels within astrocyte cyto-432 Neuron 60, November 6, 2008 ª2008 Elsevier Inc.plasm. Consistent with this, it is easy to detect glutamate immu-
noreactivity in neurons, but not in astrocytes. Furthermore, as-
trocytes in vivo do not express any of the known vesicular
glutamate transporters, nor do they express any of the compo-
nents of regulated vesicular release that mediate glutamate re-
lease in neurons (Cahoy et al., 2008). Some labs have been un-
able to find evidence for calcium-induced release of glutamate
onto postsynaptic neurons (reviewed in Agulhon et al., 2008).
Most of the arguments that astrocytes release glutamate in
response to elevated calcium in vivo are indirect and are, for in-
stance, based on blockade of a response by mGluR5 pharma-
cological blockers. However, in the mature brain mGluR5 is pri-
marily expressed by neurons. Overall, the case for regulated
release of glutamate from astrocytes onto neurons at tripartite
synapses is not convincing.
Although astrocytes do not appear to be capable of vesicular
release of the kind used by neurons, recent studies reveal that
elevated calcium in astrocytes does induce a special kind of reg-
ulated secretion from secretory lysosomes (Jaiswal et al., 2007;
Zhang et al., 2007; Li et al., 2008). Secretory lysosomes are en-
riched in certain cell types such as immune cells and glia. In
oligodendrocytes, secretory lysosomes secrete myelin proteins
and likely play a critical role in myelination (Trajkovic et al.,
2006). In astrocytes, secretory lysosomes release ATP, and
blocking release of ATP from secretory lysosomes blocks prop-
agation of calcium waves between neighboring astrocytes.
Although these studies have so far focused on astrocytes in cul-
ture, a similar mechanism of release is likely to occur in vivo given
that acutely isolated astrocytes express the genes involved in
lysosome secretion (Cahoy et al., 2008). ATP release by astro-
cytes regulates CNS synaptic transmission in vivo (Pascual
et al., 2005), and it is thus likely that this glial release in vivo
occurs from secretory lysosomes.
There are many other substances released by astrocytes that
are likely to regulate synaptic transmission. Perhaps the most in-
teresting of these is D-serine, an important neurotransmitter that
serves as a coagonist with glutamate at NMDA receptors (Mus-
tafa et al., 2004; Panatier et al., 2006). Although mRNA for its syn-
thetic enzyme serine racemase is expressed equally by neurons
and astrocytes, only glial cells can synthesize serine, so synap-
tically available D-serine is likely to be primarily made and se-
creted by astrocytes. In addition, it is very likely that astrocytes
serve as a primary supplier of the four-carbon backbone for de
novo synthesis of neuronal glutamate and GABA because pyru-
vate carboxylase is primarily found in astrocytes (Hertz et al.,
2007; Cahoy et al., 2008). Some evidence suggests that the
rate at which astrocytes supply this precursor may limit the
rate at which neurons can fire. Astrocytes also make and secrete
many unique lipids, including PUFAs, whose possible roles at
synapses have so far received little attention (Cahoy et al.,
2008). In summary, although astrocytes probably do not conduct
gliotransmission by secreting vesicular glutamate onto synap-
ses, astrocytes secrete many neuroactive substances such as
ATP and D-serine. Our understanding of how and why these
substances regulate synaptic function is in its infancy.
The Astrocyte Transcriptome
In order to gain new clues to the mysterious function of astro-
cytes and related cells such as Mu¨ller glia, several labs have
Neuron
Perspectivedeveloped new methods to isolate highly purified glial cell types
in order to extract their mRNA, gene profile it using Affymetrix
gene chips, and compare it with neurons. This has allowed elu-
cidation of the astrocyte, oligodendrocyte, neuron, and Mu¨ller
glial transcriptomes (Lovatt et al., 2007; Cahoy et al., 2008;
Roesch et al., 2008; these are available as supplemental Excel
spreadsheets from the journal web sites; the mouse all-exon
data set from Cahoy et al. consisting of 1.2 million probe sets
worth of exon expression data is too large to be posted as an Ex-
cel spreadsheet but is now available at http://innateimmunity.
mcb.harvard.edu/exonarray/cahoy.html; see Supplemental
Data, available online, for further deatils). Only a brief coverage
of a few of the interesting findings from analysis of these tran-
scriptomes is possible here. Many new astrocyte-specific genes
were identified. Aldh1L1 (Figure 2) was identified as a highly spe-
cific antigenic marker for astrocytes with a substantially broader
pattern of astrocyte expression than the traditional astrocyte
marker GFAP (a monoclonal that works well for staining rat
Aldh1L1 is now available from Neuromab, Aldh1L1-GFP mice
are available from Gensat, and Aldh1L1-Cre mice will soon be
available from Jackson Labs). The transcriptomes of oligoden-
drocytes and astrocytes were not more similar to each other
than to neurons, thus calling into question the concept of a glial
cell class. Interestingly, several evolutionarily conserved phago-
cytic pathways were found to be highly enriched in astrocytes in-
cluding the Draper/Megf10 and Mertk/integrin alpha(v)beta5
pathways, suggesting that mammalian astrocytes may be pro-
fessional phagocytes. Similarly the Draper/Megf10 pathway
Figure 2. Protoplasmic Astrocytes in the Developing Cerebral
Cortex
Protoplasmic astrocytes (green) throughout the postnatal day 7 mouse cere-
bral cortex are visualized by expression of green fluorescent protein (GFP) in
a transgenic mouse in which GFP expression is driven from a bacterial artificial
chromosome (BAC) using the Aldh1L1 promoter. Image from Gensat.org.has been previously localized to Drosophila astrocytes where it
mediates axon pruning, and recently it has been localized to
Schwann cells as well, which is interesting because Schwann
cells mediate clearance of degenerating myelin as well as elimi-
nated synapses at the developing neuromuscular junction
(Bishop et al., 2004). These findings raise the interesting possibil-
ity that astrocytes are actively mediating synapse elimination by
phagocytosis using these pathways during development, normal
adulthood, or after injury. This function is reminiscent of the role
of retinal pigment epithelial cells that mediate daily clearance of
the shed outer segments of photoreceptors via the Mertk path-
way.
One longstanding idea is that astrocytes may be critical in pro-
moting neuronal survival by releasing neurotrophic factors.
Known neurotrophic factors do not strongly promote the survival
of most types of CNS neurons the way that they do for PNS neu-
rons. It has been known for 30 years, however, that astrocytes in
culture release neurotrophic signals that strongly promote CNS
neuron survival (Banker, 1980), and that in vivo astrocyte survival
is necessary for CNS neuron survival (Wagner et al., 2006). How-
ever, what the identities of these astrocyte-secreted signals are
and how they promote neuronal survival are still unanswered
questions. Astrocytes might promote neuron survival simply by
virtue of inducing CNS neurons to form synapses, or they may
secrete other signals that activate specific neuron survival path-
ways. The transcriptomes reveal a large variety of trophic factors
made by astrocytes that suggest they may in fact contribute to
neuronal survival, and this will be interesting to explore in future
studies. One of the greatest mysteries surrounding the astrocyte
transcriptome is that the functions of most of its most highly ex-
pressed specific genes are still relatively poorly understood.
These genes include ApoE, ApoJ, MFGE8, and cystatin C. The
first three of these, however, are likely to function as lipid or
lipid-associated signal carriers in the lipoprotein particles that
astrocytes secrete, and possibly also function as opsonins to
coat unwanted debris or synapses and enable their phagocytic
clearance by astrocytes.
There are many other fundamental questions about astrocytes
that gene profiling should be helpful for in future studies. First,
the gene profiles indicate a surprising amount of regional astro-
cyte heterogeneity. As one example, astrocytes largely present
in the thalamus express high levels of the NMDA receptors
1 and 2C. Bergmann glia continue to express in the adult brain
many astrocyte genes that are otherwise only expressed by im-
mature astrocytes in postnatal brain, which suggests the possi-
bility of some unusual sustained structural plasticity of adult cer-
ebellar Purkinje cells. A better understanding of the nature of
astrocyte heterogeneity will likely provide new insight into astro-
cyte functions. Second, gene profiling will help to understand
how white matter (fibrous) and gray matter (protoplasmic) astro-
cytes compare and how they differ in function. Finally, gene pro-
filing has great potential to provide new insight into the functional
roles of reactive astrocytes.
Astrocytes, the Blood-Brain Barrier, and Disease
Vascular cells are a major cellular constituent of the brain (Fig-
ure 3) and have recently emerged as important, though relatively
neglected, contributors to brain development and function. Vas-
cular cells guide developing axons (Makita et al., 2008), provideNeuron 60, November 6, 2008 ª2008 Elsevier Inc. 433
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cells (Shen et al., 2004; Dugas et al., 2008), and provide a niche
for neural stem cells (Tavazoie et al., 2008). One role commonly
noted in textbooks for astrocytes is that they induce the blood-
brain barrier, although there is still relatively little evidence that
they do so in an uninjured brain. The blood-brain barrier is actu-
ally several different barriers that include tight junctions between
brain endothelial cells, low brain endothelial rates of endocyto-
sis, and a high level of multiple export and import transporters
(Zlokovic, 2008). A role for astrocytes has been suspected be-
cause reactive astrocytes clearly play a critical role in sealing
the barrier after brain injury (Bush et al., 1999) and because the
barrier has long been believed to be formed postnatally concur-
rently with astrocyte generation. However, recent studies have
demonstrated that the blood-brain barrier is fully intact from
the earliest time that blood vessels enter the CNS parenchyma,
about embryonic day 11 or 12 in mice (Saunders et al., 2008;
R. Daneman and B.B., unpublished data). Different signaling
pathways control different aspects of the barrier and include
Wnt signaling, which derives from neural stem cells and drives
CNS-specific angiogenesis, brain endothelial migration, and ex-
pression of at least some importers (R. Daneman, D. Agalliu,
L. Zhou, F. Kuhnert, C. Kuo, and B.B., unpublished data). In
postnatal development, after stem cells are largely depleted,
these functions may be taken over postnatally by astrocytes,
which may thus serve more of a maintenance function than an ini-
tial blood-brain-barrier-inducing function (Cahoy et al., 2008).
Given the large number of signals and cell types that participate
in controlling the blood-brain barrier, it is not surprising that so
many different brain diseases can compromise this barrier.
Because astrocytes constitute nearly half of the cells in the hu-
man brain, there is no CNS disease that does not substantially
involve astrocytes. Astrocyte swelling is a dramatic and very
harmful component of any acute neurological injury including
stroke and brain trauma, yet we still do not understand well
why astrocytes are more likely to swell than neurons and how
this swelling can be lessened. Neurological diseases, including
dysmyelinating diseases and epilepsy, can result from mutations
Figure 3. Vascular Cells Are a Major Cellular Constituent in the
Human Brain
Blood vessels represent a substantial fraction of the volume of the brain. Ves-
sels were visualized by filling them with a plastic emulsion, after which brain
parenchymal tissue was dissolved (from Zlokovic and Apuzzo, 1998).434 Neuron 60, November 6, 2008 ª2008 Elsevier Inc.of astrocyte genes. Reactive gliosis (astrocytosis) also accom-
panies every neurological disease. Although reactive astrocyto-
sis clearly is beneficial in that it can encapsulate infections and
help seal a damaged blood-brain barrier, there are many ways
in which it has been found to be harmful. Glial scarring contrib-
utes substantially to the glial cues that inhibit severed CNS axons
from regenerating (Silver and Miller, 2004). Reactive astrocytes
upregulate synapse-inducing genes such as thrombospondins,
which have the potential to help repair the brain (Liauw et al.,
2008) but may also induce unwanted synapses that can cause
epilepsy or neuropathic pain (Boroujerdi et al., 2008). In addition,
recent studies have found that sick astrocytes can release a pro-
foundly neurotoxic signal. For instance, mutant astrocytes carry-
ing the SOD1(G93A) allele release a toxic signal that rapidly kills
wild-type motor neurons (Di Giorgio et al., 2007; Nagai et al.,
2007; Lobsiger and Cleveland, 2007).
A critically important area of neuroscience research today is to
understand the pathophysiology of stroke, one of the most com-
mon neurological diseases. Other than clot-busting drugs, there
are not yet good treatments that minimize brain tissue loss and
dysfunction after stroke. Perhaps before we can successfully
treat stroke, we need to more fundamentally understand why
the CNS is so much more vulnerable to ischemia than non-
CNS tissues. Thirty years ago in medical school, I was taught
that neurons are more vulnerable to ischemia than any other
cell type in the body. Excitotoxicity is certainly a central element
of ischemic damage that is unique to the CNS. But in the light of
modern-day knowledge, I often wonder whether it is also possi-
ble that neurons have exactly the same intrinsic vulnerability to
ischemia as any other cell type. The greater brain vulnerability
to ischemia might simply reflect the lower redundancy and repair
ability of the brain compared those of the liver or the kidney. Or
alternatively it might reflect the special nature of the division of
metabolic labor between neurons and glia. It is a good time for
more graduate students and postdocs to begin addressing
these questions.
How Do Oligodendrocytes Myelinate?
If the close association of astrocytes with neurons reflects the
importance of their functional interactions, perhaps there is no
more intimate cellular interaction than that of oligodendrocytes
and Schwann cells wrapping their membranes around axons
to form myelin. In addition to providing insulation and trophic
support to neurons, myelinating glia are active participants in
nervous system function, sculpting the structural and electrical
properties of axons by controlling their diameter, as well as the
spacing and clustering of ion channels at nodes and paranodes.
Schwann cells also help promote the regeneration of axons and
the formation and function of synapses at the neuromuscular
junction. Surprisingly, our understanding of how Schwann cells
and oligodendrocytes myelinate is still very limited. Oligodendro-
cytes are generated by OPCs that migrate from their germinal
zones during development and after injury to regions where
axons are unmyelinated, ensheath these axons, and then wrap
them. Whereas the mechanisms of wrapping remain largely un-
known, neuregulin-1 has been identified as a critical axonal sig-
nal controlling myelination in the PNS, and gliomedin has been
identified as a key Schwann cell signal that triggers clustering
Neuron
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Brinkmann et al., 2008). Although it was long thought that the sig-
nals in the CNS and PNS would be the same, differential regula-
tion of sensory axonal signals by NGF indicated that distinct
mechanisms are involved (Chan et al., 2004). Indeed, the neure-
gulin-1 isoform controlling Schwann cell myelination turned out
not to be essential for CNS myelination, and gliomedin has not
been implicated in ion channel clustering induced by oligoden-
drocytes. Similarly, the molecular mechanisms that enable oligo-
dendrocytes to recognize, ensheath, and wrap axons are not
known. Progress has been slow in part because myelination is
largely a vertebrate adaptation, so forward genetic screens
have not been practical. In addition, knockout mice that do not
express major myelin proteins and lipids are surprisingly good
at myelinating, with the exception of myelin basic protein, which
is clearly required for wrapping in the CNS (but not PNS). As for
the astrocyte transcriptome, the oligodendrocyte transcriptome
has revealed a large number of highly expressed, oligodendro-
cyte-specific molecules whose roles are mostly unknown (Niel-
sen et al., 2006; Cahoy et al., 2008). Zebrafish has emerged as
a powerful new genetic model system for the study of myelina-
tion and node of Ranvier formation (Pogoda et al., 2006).
Another long-time limitation in studying the molecular basis of
CNS myelination has been the lack of a rapidly myelinating cul-
ture system. In general, when CNS cultures consisting of mixed
neurons and glia are prepared, they need to be cultured for at
least 30 days before substantial myelination occurs. A recently
developed coculture system that enables rapid myelination of
CNS axons offers new opportunities for molecular dissection
of multiple stages of myelination. Purified CNS neurons can be
cultured as ‘‘reaggregates’’ so that they extend dense beds of
axons, which can then be seeded with purified OPCs in a se-
rum-free medium (Watkins et al., 2008; Figure 4). In this system,
myelination occurs in three stages that are under differential con-
trol. First, OPCs are largely inhibited from differentiating into ol-
igodendrocytes by axonal signals. Although all of these inhibitory
axonal signals are not yet known, Notch ligands such as Jag-
ged1 contribute, because genetic or pharmacologic disruption
of Notch1 signaling favors oligodendrocyte differentiation. De-
spite expressing myelin proteins, these newly differentiated oli-
godendrocytes do not robustly ensheath axons unless gamma
secretase activity within the oligodendrocytes is inhibited either
genetically or pharmacologically. Interestingly, the ensheath-
ment of multiple axons by each oligodendrocyte seems to be
a coordinated event. Oligodendrocytes, observed by time-lapse
microscopy, do not ensheath their various axons sequentially at
different times, but rather ensheath them all within only a brief
period, typically just 12–18 hr. For this concurrent ensheathment
to be triggered, an OPC seems to need to contact a sufficient
number of axons within the first 12 hr or so of its differentiation.
This implies the existence of a nuclear program that controls en-
sheathment: cleavage of a gamma secretase substrate may re-
lease a C-terminal fragment that enters the nucleus and inhibits
ensheathment; reduction of gamma secretase activity would
then regulate this nuclear program, enabling ensheathment of
multiple axons at once. One hypothesis suggested by these find-
ings is that an unidentified axonal signal triggers ensheathment
by inhibiting gamma secretase activity within oligodendrocytes.Finally, simplified culture systems have revealed that myelinating
oligodendrocytes receive a helping hand from astrocytes, partic-
ularly in the later stage of wrapping (Ishibashi et al., 2006; Soren-
sen et al., 2008; Watkins et al., 2008). The complete picture of the
ways in which astrocytes promote more rapid wrapping is not yet
clear, but could include providing both signals, such as LIF, and
material contributions in the form of packaged lipids. Some evi-
dence suggests that this support may be preferentially provided
by white-matter- rather than gray-matter-derived astrocytes. By
characterizing astrocyte functions, and by identifying the gamma
secretase substrate within oligodendrocytes, which may con-
nect an axonal signal with a nuclear program in oligodendro-
cytes, it should be possible to make future steps forward in
understanding the molecular basis of CNS myelination.
Many diseases of the nervous system involve myelin. Multiple
Sclerosis is one of the most common neurological diseases. It in-
volves demyelination due to an autoimmune attack on myelin
and oligodendrocytes. Although in most cases of relapsing and
remitting Multiple Sclerosis, it appears that there is initial remye-
lination due to the generation of new oligodendrocytes and new
myelin, at some point in the disease this repair process fails. It is
not known whether repair fails because of exhaustion of new
OPCs, a deficiency in the relevant axonal signals or electrical ac-
tivity that induces OPC proliferation and myelination, a diversion
of OPCs into an astrocyte differentiation pathway, or the devel-
opment of inhibitors that prevent migration or myelination by
OPCs. The answer may lead to new drugs that promote myelin
repair. Oligodendrocytes are also lost in brain trauma and spinal
cord injury either directly or as an indirect result of axon injury
and degeneration. Axonal signals, not yet identified, are required
for the survival of oligodendrocytes. Reciprocally, demyelinated
Figure 4. Myelinating Oligodendrocytes in Coculture with Retinal
Ganglion Cells
Green represents myelin basic protein immunoreactivity, which labels oligo-
dendrocytes and myelin. Blue is the DAPI nuclear dye. Red is NG2 chondroitin
sulfate proteoglycan immunoreactivity, which labels oligodendrocyte precur-
sor cells. Cocultures were prepared as described in Watkins et al. (2008).Neuron 60, November 6, 2008 ª2008 Elsevier Inc. 435
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this failure mechanism is also unclear.
Surprisingly, there is new evidence that major depressive dis-
order may involve a massive loss of oligodendrocytes and myelin
within the temporal lobe. When mRNA extracted from human
temporal lobes was analyzed by gene profiling, a 3-fold de-
crease in all oligodendrocyte genes was found (Aston et al.,
2005). These findings corresponded well to a histological loss
of oligodendrocytes that had been observed in previous studies,
and occurred regardless of whether the patients had been
treated with antidepressant medication. Over the past 50 years
of intensive study, loss of myelin is the most dramatic abnormal-
ity to ever be reported in this very common disorder. A long-pre-
vailing view has been that depression is a disorder caused by low
CNS serotonin levels, but it is interesting to note that oligoden-
drocytes express high levels of dopa decarboxylase (Cahoy
et al., 2008), a serotonin synthetic enzyme. These findings sug-
gest the possibility that low serotonin levels are an effect rather
than a cause of depression. It is critical that additional studies
be conducted to confirm these findings, because if they are cor-
rect, there are important implications for developing new treat-
ments. Although based on rodent studies, it has long been
thought that oligodendrocytes do not turn over appreciably
during a lifetime, it is possible in humans that they are slowly re-
placed, much as is now known to occur for hippocampal neu-
rons. If this rate of new generation is even slightly lessened, for
instance by stress, this could lead over time to substantial loss
of myelin. If so, new treatments that promote the generation of
new oligodendrocytes might be beneficial.
What Are the Roles of Microglia?
Immune system cells called microglia constitute about 10% of
CNS glia (Hanisch and Kettenmann, 2007; Soulet and Rivest,
2008). Much mystery surrounds the functions of microglia in
health and in disease. Like perivascular macrophages of the
brain, microglia are derived from uncommitted myeloid progen-
itor cells that invade the brain neonatally (Santambrogio et al.,
2001). In vitro, these myeloid progenitor cells are bipotential; de-
pending on context, they can become phagocyte-like cells or im-
mature dendritic-like cells. Within the normal brain, it is unclear
exactly what their phenotype is; many or all may retain a relatively
uncommitted state. Like other glial cell types, much of their func-
tion remains mysterious, and like reactive astrocytes, there has
been much debate about whether their functions are helpful or
harmful. There is increasing evidence for microglial heterogene-
ity within the brain, with antigen-presenting dendritic cell types
present even within uninjured brain tissue (Carson et al., 2007;
Bulloch et al., 2008; Bailey-Bucktrout et al., 2008; Gowing
et al., 2008). Normally macrophages are situated in the perivas-
cular space, whereas microglia are located within the brain pa-
renchyma. Within the normal brain, microglia appear to act as
sensors of the extracellular environment, rapidly responding to
and potentially communicating changes or injury to surrounding
neural cells or non-CNS immune cells. Recent in vivo time-lapse
imaging has revealed dynamic interactions between microglia
and neurons in the brain following lesion or injury (Davalos
et al., 2005; Nimmerjahn et al., 2005). Although microglia display
at least some phagocytic ability, so far they do not appear to436 Neuron 60, November 6, 2008 ª2008 Elsevier Inc.have the strong professional phagocytic ability exhibited by ac-
tivated macrophages. Many recent papers have found that
amyloid deposits and degenerating CNS myelin are far more ro-
bustly phagocytosed by macrophages than microglia. Dendritic
microglia have recently been demonstrated to present myelin
antigens to T cells within the brain, where they play a critical
role in driving the progression of relapsing experimental autoim-
mune encephalomyelitis, a mouse model of the demyelinating
disease Multiple Sclerosis (Miller et al., 2007).
Activated microglia secrete high levels of many cytokines in-
cluding TNFa, a proinflammatory cytokine involved in demyelin-
ating and other diseases. TNFa signals directly to lymphocytes
and macrophages to control their function, but recent studies
have called attention to its actions on neural cells as well. Micro-
glial-derived TNFa plays a critical role in promoting generation of
new oligodendrocytes in mouse models of demyelination (Arnett
et al., 2001). Cytokines released by microglia weaken the integ-
rity of the blood-brain barrier in brain inflammation. TNFa even
plays a role in controlling normal function and plasticity of neural
circuits in vitro and in vivo (Stellwagen and Malenka, 2006;
Kaneko et al., 2008). Blockade of activity in hippocampal neu-
rons scales up the size of their synaptic inputs, an effect depen-
dent on microglia-derived TNFa (although astrocytes in culture
have frequently been suggested to secrete TNFa, it is likely
that this TNFa derives from microglia, which generally heavily
contaminate astrocyte cultures). Astrocytes and OPCs express
TNFa receptors, but it is unclear whether neurons normally do.
Thus, it is possible that microglial TNFa exerts its effects on neu-
rons indirectly by acting on synaptic astrocytes. The effects of
cytokines on neuronal activity, both normally and after injury,
are worthy of much further attention.
In addition to affecting synaptic activity, emerging data point
to an important role for microglia during CNS development in
mediating the selective elimination of inappropriate synaptic
connections during the formation of mature neural circuits. The
initiating protein of the classical complement cascade called
complement component 1 q (C1q) is highly deposited on many
synapses throughout the developing CNS (Stevens et al.,
2007). Little C1q is present in the adult CNS, but postnatally, im-
mature astrocytes release a signal that induces neuronal (and
possibly also microglial) expression and secretion of C1q. Al-
though neuronal C1q was observed primarily within the retina,
microglia throughout the developing, but not adult, CNS express
extremely high levels of C1q. Secreted C1q binds to and tags de-
veloping synapses. Then, at some or all of these synapses, the
classical complement cascade becomes activated, leading to
the synaptic deposition of the complement component C3.
Mice deficient in complement protein C1q or C3 fail to eliminate
many CNS synapses, as shown by the failure of anatomical re-
finement of retinogeniculate connections and the retention of ex-
cess functional retinal innervation by lateral geniculate neurons.
How do complement-tagged synapses get removed? It is likely
they are phagocytosed by microglia. Microglia express high
levels of C3 receptors, and binding of C3 to this receptor signals
microglia and macrophages to phagocytose. In fact, microglia
are well known to phagocytose synaptic terminals of spinal
and hypoglossal motor neurons following injury in a process
known as synaptic stripping, although it is not yet known whether
Neuron
Perspectivethis process is also complement cascade dependent. These
findings add to the growing evidence that immune system mol-
ecules are crucial for the patterning of neural circuits (Boulanger
and Shatz, 2004; Huh et al., 2000) and support a model in which
unwanted synapses are tagged by complement proteins for
elimination by phagocytic cells.
These findings indicate that the immune system plays impor-
tant roles in normal brain function and raises the question of
whether it plays similar roles in brain disease. Interestingly,
C1q levels have been demonstrated to be substantially elevated
in most acute and chronic CNS diseases, particularly neurode-
generative diseases. For instance, C1q become elevated and lo-
calized to retinal synapses as the earliest manifestation of the
disease process in a mouse model of glaucoma (Stevens et al.,
2007). In Alzheimer’s disease, C1q levels within the CNS have
been found to be as much as 70-fold elevated. This is interesting
because Alzheimer’s disease is a disease of massive synapse
loss. It has been estimated that by the time even the earliest cog-
nitive loss can be detected in an Alzheimer’s patient, some
regions of their brain have already lost as many as 80% of their
synapses. So far, mouse models of Alzheimer’s disease have
not exhibited such a profound synapse loss. Nonetheless, C1q
deficiency has been shown to be predictive in a mouse model
of Alzheimer’s disease (Fonseca et al., 2004). Thus, classical-
complement-cascade-mediated synapse loss may be a central
feature of neurodegenerative diseases such as Alzheimer’s dis-
ease, ALS, Multiple Sclerosis, and glaucoma. If so, drugs that
block synaptic complement cascade activation have the poten-
tial to minimize neurodegeneration in these diseases.
The role of microglia in neurological disease is now the matter
of much intrigue and debate. Microgliosis and reactive astrocy-
tosis generally occur together, but it is not known whether there
is a causal connection and if so in which direction. Astrocytes re-
lease signals such as CSF-1 and ATP that can signal to micro-
glia, whereas microglia release signals such as TNFa that can
signal to astrocytes. Nor is there agreement on whether lessen-
ing either type of gliosis will be helpful or harmful. The answer
may well depend on the type and stage of each disease process.
This is an emerging, understudied area of research that will un-
doubtedly remain fruitful for a long time, and it is likely to teach
us much about normal and abnormal brain function.
Could Glial Cells Be Important Drug Targets?
As we have seen, virtually every aspect of brain development
and function involves a neuron-glial partnership. Therefore, the
answer to every important question about brain disease will
also involve glia. The most common brain diseases include trau-
matic brain injury, stroke, spinal cord injury, Multiple Sclerosis,
epilepsy, Alzheimer’s disease, Parkinson’s disease, and ALS,
Down’s syndrome, glioma, major depressive disorder, and au-
tism. Other than palliative treatments, we currently have few
effective treatments that block the underlying disease process
for any of these disorders, and we cannot repair and restore
a damaged brain yet. An obvious reason is that for each of these
diseases we still do not understand many basic aspects of their
pathophysiology. In every one of these diseases, glial cells are
central contributors, yet their roles are often neglected (Miller,
2005). If we want to keep neurons from dying or misbehavingin these diseases, we must understand how glial pathology con-
tributes to neuronal dysfunction and vice versa (Lobsiger and
Cleveland, 2007). Over 1000 drug trials for stroke have now failed
(O’Collins et al., 2006). In most of these trials, neurons were ex-
clusively targeted, for instance using drugs that blocked neuro-
nal glutamate receptors. Yet the extent to which astrocytes are
killed in stroke or in neurodegenerative processes has received
relatively little attention. If the glia that support the neurons are
killed, how can the neurons be saved by just targeting the neu-
rons? Quite possibly saving astrocytes from dying in neurologi-
cal disease would be a far more effective strategy than trying
to save neurons (glia already know how to save neurons,
whereas neuroscientists still have no clue).
Therefore if we are to make progress in understanding normal
and abnormal neurobiology, we have to start teaching neurobiol-
ogists more about how neurons interact with other cell types
including glia, vascular cells, and immune cells. The explosion
in interest in neurobiology among young people today has lead
to the creation of an undergraduate major in neurobiology at
most universities, which has arguably substantially undermined
interdisciplinary training of neurobiologists. An undergraduate
degree in engineering, physics, bioinformatics, immunology, or
genetics, perhaps along with a minor in neuroscience, would
make far more sense. One solution may be to offer undergradu-
ates additional options, perhaps the option of a major in neuro-
engineering or neurogenetics. There is much to be said for the
creation of a coterm masters degree in human biology and dis-
ease (the equivalent of the first year and a half or so of medical
school) for undergraduates interested in translational research
or obtaining a broader perspective of brain function in the con-
text of a whole organism, but not interested in clinical practice
(see http://msm.stanford.edu). Such programs would help to de-
ploy our young scientists far more effectively. It is unfortunate
that today’s conservative funding climate encourages, indeed al-
most mandates, students to continue in their own labs working
on exactly the same focused areas of research that they trained
in. Having 20,000 neuroscientists that study LTP while only 20
are studying glia simply makes no sense. In the growth of knowl-
edge, as in the growth of savings, diversification makes all the
difference.
The pipelines are now starting to run dry at major pharmaceu-
tical companies. A business model does not seem to work well
when it comes to understanding pathophysiology because of
the high risk nature of this research. But new treatments will
only come when we have a deep mechanistic understanding of
disease processes. It is therefore urgent that more academic sci-
entists be involved in this quest. If we are to develop new treat-
ments more rapidly, then academia, pharmaceutical companies,
philanthropists, venture capitalists, and nonprofit foundations
will have to innovate completely new ways of working together.
Interesting new attempts at a more collaborative approach
include the Adelson Medical Foundation, Fast Forward (www.
fastforward.org), the CHDI Foundation (Pacifici and Rankin,
2008), and the Myelin Repair Foundation (www.myelinrepair.
org). Let’s all work together—if we can cure neurological dis-
eases, there will be more than enough credit to share.
And please don’t forget the glia! Quite possibly the most im-
portant roles of glia have yet to be imagined.Neuron 60, November 6, 2008 ª2008 Elsevier Inc. 437
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